Yang, L., & Ma, A. (2023). Cost-utilities Analysis of Polatuzumab Vedotin Combined with Bendamustine and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma Which Is Unsuited for Hematopoietic Stem Cell Transplantation. Frontiers in Business, Economics and Management, 8(3), 178-184. https://doi.org/10.54097/fbem.v8i3.7835